? CANCER RESEARCH TRAINING AND EDUCATION COORDINATION The Center for Cancer Mentoring, Education, Leadership, and Oncology-related Training (CAMELOT) serves as the centralized hub for the Ohio State University Comprehensive Cancer Center (OSUCCC) fostering cancer research and education, and disseminating those opportunities. CAMELOT?s efforts begin at the high school level, continue through undergraduate and graduate training, and then extend through post-doctoral training and into early faculty development and mentoring. CAMELOT is directed by Dr. Lawrence Kirschner, the OSUCCC Associate Director of Training and Education. He is assisted by Drs. Deepa Sampath, Elizabeth Klein, and Rosa Lapalombella. CAMELOT coordinates training and education programs through: 1) direct programs (e.g., for high school, Pelotonia fellows, external undergraduate student summer rotations including students from Ohio Historically Black Universities and Colleges); 2) integrating College of Medicine (COM) programs with OSUCCC activities and opening them to trainees and junior faculty outside the COM; 3) supporting grant submissions by junior faculty; and 4) supporting training grant submissions. The Pelotonia Fellowship Program (PFP), a major commitment by the OSUCCC to fellowship training, has been in existence for 10 years, and provides stipends and research support to fellows from the undergraduate to the postdoctoral fellowship level. OSUCCC provides $2-3M/year to support the PFP. During the current grant cycle, 251 pre- and postdoctoral fellowships awarded, of which 155 had mentors who were OSUCCC members from all five of the OSUCCC research programs and 10 of the 15 OSU Colleges. More than 90% of these trainees are currently active as cancer researchers. New programs developed by CAMELOT include two cancer research-focused pipeline programs, one for local underrepresented minority high school students and another for current OSU undergraduates.
The Specific Aims are to: 1) provide integration and coordination of training opportunities for cancer research across the OSUCCC and university ecosystem, and region, including high schools and colleges; 2) enhance formalized programming for cancer-based mentoring including both peer-to-peer and senior-to-junior mentoring; and, 3) develop an integrated system to enable assessment and outcome tracking for trainees at all levels of engagement with the OSUCCC (grants, papers, academic positions, etc.) to foster continuous quality improvement in educational and career development activities. The OSUCCC is planning robust faculty recruitment around strategic research priorities that will create new opportunities for education and training. To accommodate this, a bigger pipeline for training is planned in the next funding cycle. The OSUCCC will: 1) expand graduate and postgraduate training slots and programs for high school students; 2) establish the Young Cancer Investigator Faculty Academy that focuses on OSUCCC wet-lab researchers to support development of independent research programs; 3) establish a uniform tracking system for trainees; and 4) foster submissions of R25 and T32 training grants, including supplements.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Wang, Yufeng; Dong, Wenjuan; Zhang, Yibo et al. (2018) Dependence of innate lymphoid cell 1 development on NKp46. PLoS Biol 16:e2004867

Showing the most recent 10 out of 2602 publications